Astrazeneca plc
CH ˙ SWX ˙ GB0009895292
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT
SecurityCH:AZN / Astrazeneca plc
InstitutionBLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A
Latest Disclosed Ownership25,583 shares
Latest Disclosed Value $ 3,560,364
BLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A reports 1.92% increase in ownership of AZN / Astrazeneca plc

On August 28, 2025 - BLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A filed a NPORT-P form disclosing ownership of 25,583 shares of Astrazeneca plc (CH:AZN) valued at $3,560,364 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 25,102 shares of Astrazeneca plc. This represents a change in shares of 1.92% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-28 2025-06-30 NP AstraZeneca EC GB0009895292 25,583 481 1.92 3,560 -3.42 0.7522
2025-05-28 2025-03-31 NP AstraZeneca EC GB0009895292 25,102 19,045 314.43 3,686 367.17 0.8282
2025-02-25 2024-12-31 NP AstraZeneca EC GB0009895292 6,057 3,661 152.80 790 130.03 0.2121
2023-08-25 2023-06-30 NP AstraZeneca EC GB0009895292 2,396 -1,638 -40.60 343 -38.53 0.0872
2023-05-26 2023-03-31 NP AstraZeneca EC GB0009895292 4,034 4,034 559 0.1453
2021-08-26 2021-06-30 NP AstraZeneca EC GB0009895292 0 -6,192 -100.00 0 -100.00
2021-05-27 2021-03-31 NP AstraZeneca EC GB0009895292 6,192 -3,765 -37.81 618 -37.70 0.1431
2021-02-25 2020-12-31 NP AstraZeneca EC GB0009895292 9,957 -373 -3.61 993 -12.06 0.2356
2020-11-25 2020-09-30 NP AstraZeneca EC GB0009895292 10,330 366 3.67 1,129 8.88 0.2947
2020-08-27 2020-06-30 NP AstraZeneca EC GB0009895292 9,964 6,396 179.26 1,037 226.81 0.2801
2020-06-01 2020-03-31 NP AstraZeneca EC GB0009895292 3,568 585 19.61 318 19.17 0.1002
2019-11-27 2019-09-30 NP AstraZeneca EC GB0009895292 2,983 2,983 266 0.0630
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.